Targeted inhibition of FBXL2 confers susceptibility of HER2-negative breast cancer to trastuzumab deruxtecan.

求助中 10 由 kj 发布于 2026/2/3 0:45:35

DOI:10.1038/s43018-025-01112-z
作者：Jing Xu,?Jing Liu,?Yang Liu,?Ting Huang,?Yong Yi,?Ruixiao Bai,?Haorui Zheng,?Xiaoli Chen,?Jiexin Gao,?Xin Lian,?Rongtian Guo,?Chuan Xu,?Qintong Li,?Yujun Zhang,?Yang Cao,?Peng Mi,?Zhi-Xiong Jim Xiao,?
文献类型：期刊论文
补充材料：只需要正文

Nature

Abstract：Trastuzumab deruxtecan (T-DXd), an anti-HER2-drug conjugate, has transformed treatment for HER2-expressing solid tumors. However, heterogeneous intratumoral HER2 expression, particularly hig

应助信息

等您来应助

上传文件

4小时前

Book学术机器人

2026/2/3 0:45:35 未找到该文献，机器人已退出，请等待人工下载

2026/2/3 0:45:35 Book学术AI机器人收到请求，开始寻找文献

2026/2/3 0:45:35 已向机器人发送请求

4小时前

kj 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierHydrophilicity regulation of carbon nanotubes as phase-change materials for thermal energy storage